SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy trading activity as investors react to its upcoming inclusion in the S&P 500 index, a move that is expected to trigger significant passive buying. The stock continues to be a central talking point in the AI infrastructure sector, with community members heavily debating its valuation and growth potential against the backdrop of recent major strategic investments from Nvidia.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to significant natural gas discoveries and reserves growth, which investors see as a critical asset amid the ongoing energy crisis and regional geopolitical instability. The community is actively tracking the stock's low float and massive volume spikes, with many debating its potential for a sustainable rally versus risks of volatility and future equity offerings.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent and intensifying market speculation that the French biotech company is a high-priority takeover target for major pharmaceutical players, particularly Eli Lilly. While the company has previously dismissed such rumors as market noise, investors are actively analyzing unusually high trading volumes and bullish options activity, fueling community debate over a potential buyout premium and the company's long-term commercialization prospects.

Tower Semiconductor Ltd. engages in providing semiconductor solutions. It also offers technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical, and aerospace and defense. It focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Its designs enable a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. The company was founded in 1993 and is headquartered in Migdal Haemek, Israel.

Tower Semiconductor Ltd.

Tower Semiconductor is generating significant investor buzz fueled by a recent development agreement with Lightwave Logic to integrate electro-optic polymer modulators into its silicon photonics platform. Community discourse is heavily focused on the company's deepening involvement in the AI networking and data center supply chain, with many highlighting its strategic value as a specialized foundry for optical interconnect technology.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is gaining traction as investors highlight the community's relentless, 24/7 focus on building a permissionless brand through various real-world initiatives, including apparel, energy drinks, and merchandise. Supporters are actively encouraging others to research the project and its ecosystem, emphasizing a long-term 'conviction' play over short-term speculative trading.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors debate its potential integration into upcoming payment systems on X, while the community remains divided between bullish sentiment regarding its role in a broader crypto rally and skepticism about its long-term utility. Traders are actively watching technical indicators and social media activity to gauge whether the token will break its current consolidation pattern or succumb to ongoing market volatility.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a major focus for traders following a significant stock price run-up driven by positive clinical trial data and an upsized public offering that strengthened the company's cash position. While the community is actively debating the potential for a short squeeze and future acquisition by larger biotech firms, others are focused on the risks associated with stock dilution and the long, binary nature of clinical development.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing intense volatility following the unsealing of a federal indictment charging its co-founder and other associates with a massive scheme to smuggle restricted AI hardware to China. While the company stated it is not a named defendant and is cooperating with authorities, investors are actively debating whether this indicates deeper systemic issues or if the sell-off is a temporary overreaction, with many closely watching for potential fallout in the company's relationship with major suppliers like Nvidia.

Hesai Group engages in the development, manufacture and sale of three-dimensional light detection and ranging(lidar) solutions. The company’s lidar products enable a broad spectrum of applications across passenger and commercial vehicles with advanced driver assistance systems (ADAS) and autonomous vehicle fleets. The company was founded by Yi Fan Li, Kai Sun, and Shao Qing Xiang in October 2014 and is headquartered in Shanghai, China.

Hesai Group - ADR

Hesai Group is trending following a strategic partnership with Mercedes-Benz to integrate its LiDAR technology into global vehicle models, signaling a significant expansion of its reach beyond the Chinese market. The community is actively debating the implications of this deal alongside recent short-seller reports and ongoing geopolitical scrutiny regarding the company's ties to the Chinese military.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is trending higher following positive clinical trial results where its tirzepatide treatment outperformed Novo Nordisk's CagriSema in a head-to-head weight loss study. Investors are actively discussing the widening performance gap between the two pharma giants, while simultaneously speculating on future oral drug approvals and potential market share shifts in the obesity sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial

B. Riley Financial upgraded Arcturus Therapeutics to a "strong-buy" rating in a research report on Tuesday...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock...

Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial

B. Riley Financial started coverage on Arcturus Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $22.00 target price for the company...

Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing

Arcturus Therapeutics (NASDAQ:ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA...

Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Arcturus Therapeutics in a research note...

Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price

Citigroup reduced their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday...

Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...

ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT

ARK Investment Management LLC increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.2% in the 3rd quarter, according to the company in its most...

Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price

Citigroup upped their target price on shares of Arcturus Therapeutics from $7.00 to $8.00 and gave the company a "neutral" rating in a report on Wednesday...

Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00

Piper Sandler dropped their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc